What peptide acts like Ozempic?

Anyone searching for "a peptide that acts like Ozempic" is usually searching for semaglutide's effects under another name. Semaglutide is a modified GLP-1 analogue (94% homologous to the human hormone, per its FDA label) that suppresses appetite, slows gastric emptying, and improves glycemic control. Its benchmark result: STEP 1 (n=1,961) reported 14.9% mean weight loss vs 2.4% for placebo over 68 weeks at the 2.4 mg weekly dose. The identical molecule is sold as Wegovy (weight management) and Rybelsus (oral tablets)—see the semaglutide catalog entry.

Three regulated or clinical-stage peptides work the same appetite-and-incretin territory, each with named trials and hard numbers:

• Liraglutide (Victoza/Saxenda) — the once-daily predecessor GLP-1 agonist. In the SCALE trial (n=3,731), liraglutide 3.0 mg produced a mean 8.4 kg loss vs 2.8 kg for placebo over 56 weeks—real, but roughly half of semaglutide's relative effect.
• Tirzepatide (Mounjaro/Zepbound) — a peptide agonist of both GIP and GLP-1 receptors. In SURMOUNT-1 (n=2,539), the 15 mg dose produced 20.9% mean weight loss vs 3.1% for placebo over 72 weeks—numerically beyond semaglutide's trial results.
• Retatrutide — an investigational triple agonist (GLP-1, GIP, glucagon receptors). In a phase 2 trial (n=338), the 12 mg dose produced 24.2% mean weight loss at 48 weeks—striking, but still phase 2: not approved, with phase 3 outcomes pending.

For a fuller side-by-side, see semaglutide vs tirzepatide.

What about the "Ozempic alternative" peptides sold on research-chemical sites— AOD-9604, various "GLP-1 fragment" vials, or gray-market semaglutide itself? None of them belongs on the list above. They either act on different pathways with little or no controlled human weight-loss data, or they claim to be the same molecule without the verified identity and purity that the approved products carry. Acting "like Ozempic" is an evidentiary claim, and in this category only the trialed incretin drugs have earned it.

It is tempting to treat "acts on GLP-1 receptors" as "acts like Ozempic," and trial headlines invite ranking these drugs on a single weight-loss number. But cross-trial comparisons are only rough guides—different populations, durations, and designs—and the differences beyond the headline number are the clinically important part:

• Different receptors, different profiles. Adding GIP or glucagon activity changes efficacy, side-effect balance, and dosing—tirzepatide and retatrutide are new molecules with their own trials, not stronger Ozempic.
• Different regulatory status. Semaglutide, tirzepatide, and liraglutide are approved with defined indications; retatrutide is still investigational.
• Different evidence depth. Semaglutide alone has multi-year outcome data— SELECT (n=17,604) showed a 20% cut in major cardiovascular events over a mean 39.8 months. A molecule can match Ozempic's weight numbers without yet matching its safety record.
• Shared side-effect territory, drug-specific details. GI effects dominate across the class—in STEP 1, 4.5% of semaglutide participants stopped for GI events vs 0.8% on placebo—but each label carries its own warnings, titration schedule, and contraindications, which is why switching between these drugs is handled as a prescribing decision rather than a substitution.

Finally, the sound-alike products to be wary of: gray-market vials sold as "GLP-1 peptides" or research-grade semaglutide. The FDA warns that unapproved versions may contain different salt forms and have generated adverse events from dosing errors (FDA drug alert). A molecule that "acts like Ozempic" only does so reliably when its identity, dose, and purity are verified—which is precisely what approval provides. More context: Are GLP-1 drugs considered peptides? and semaglutide vs research peptides for weight loss.